857 related articles for article (PubMed ID: 18024400)
21. Allogeneic haemopoietic cell transplants in Australia, 1996--a multi-centre retrospective comparison of the use of peripheral blood stem cells with bone marrow.
Nivison-Smith I; Bradstock KF; Szer J; Durrant S; Dodds A; Hermann R; Schwarer AP; Gibson J; To LB; Arthur C;
Bone Marrow Transplant; 2001 Jul; 28(1):21-7. PubMed ID: 11498740
[TBL] [Abstract][Full Text] [Related]
22. Comparable outcomes of allogeneic peripheral blood versus bone marrow hematopoietic stem cell transplantation from a sibling donor for pediatric patients.
Kim BK; Hong KT; Choi JY; Kim H; Park HJ; Kang HJ
Ann Hematol; 2024 Jun; 103(6):2051-2058. PubMed ID: 38594416
[TBL] [Abstract][Full Text] [Related]
23. One-year cyclosporine prophylaxis reduces the risk of developing extensive chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplantation.
Mengarelli A; Iori AP; Romano A; Cerretti R; Cerilli L; De Propris MS; Fenu S; Moleti ML; De Felice L; Girelli G; Arcese W
Haematologica; 2003 Mar; 88(3):315-23. PubMed ID: 12651271
[TBL] [Abstract][Full Text] [Related]
24. Unrelated donor peripheral blood stem cell transplants incorporating pre-transplant in-vivo alemtuzumab are not associated with any increased risk of significant acute or chronic graft-versus-host disease.
Shaw BE; Apperley JF; Russell NH; Craddock C; Liakopoulou E; Potter MN; Wynn R; Gibson B; Pearce RM; Kirkland K; Lee J; Madrigal JA; Cook G; Byrne JL
Br J Haematol; 2011 Apr; 153(2):244-52. PubMed ID: 21382020
[TBL] [Abstract][Full Text] [Related]
25. Differences between graft product and donor side effects following bone marrow or stem cell donation.
Favre G; Beksaç M; Bacigalupo A; Ruutu T; Nagler A; Gluckman E; Russell N; Apperley J; Szer J; Bradstock K; Buzyn A; Matcham J; Gratwohl A; Schmitz N;
Bone Marrow Transplant; 2003 Nov; 32(9):873-80. PubMed ID: 14561987
[TBL] [Abstract][Full Text] [Related]
26. Disease- or therapy-related bone marrow damage cannot be overcome by changes in stem cell source or dose in allogeneic transplantation.
Novotny JR; Rosenthal C; Elmaagacli AH; Dürig J; Beelen DW; Dührsen U
Eur J Haematol; 2004 Jul; 73(1):1-9. PubMed ID: 15182331
[TBL] [Abstract][Full Text] [Related]
27. Peripheral blood is safer than bone marrow as a source of hematopoietic progenitors in patients with myelodysplastic syndromes who receive an allogeneic transplantation. Results from the Spanish registry.
del Cañizo MC; Martínez C; Conde E; Vallejo C; Brunet S; Sanz G; Mateos MV;
Bone Marrow Transplant; 2003 Nov; 32(10):987-92. PubMed ID: 14595386
[TBL] [Abstract][Full Text] [Related]
28. Outcome after autologous and allogeneic stem cell transplantation for patients with multiple myeloma: impact of graft-versus-myeloma effect.
Alyea E; Weller E; Schlossman R; Canning C; Mauch P; Ng A; Fisher D; Gribben J; Freeman A; Parikh B; Richardson P; Soiffer R; Ritz J; Anderson KC
Bone Marrow Transplant; 2003 Dec; 32(12):1145-51. PubMed ID: 14647268
[TBL] [Abstract][Full Text] [Related]
29. Similar outcome after unrelated allogeneic peripheral blood stem cell transplantation compared with bone marrow in children and adolescents.
Remberger M; Ringdén O
Transplantation; 2007 Aug; 84(4):551-4. PubMed ID: 17713443
[TBL] [Abstract][Full Text] [Related]
30. Impact of AB0-blood group incompatibility on the outcome of recipients of bone marrow transplants from unrelated donors in the Japan Marrow Donor Program.
Kimura F; Sato K; Kobayashi S; Ikeda T; Sao H; Okamoto S; Miyamura K; Mori S; Akiyama H; Hirokawa M; Ohto H; Ashida H; Motoyoshi K;
Haematologica; 2008 Nov; 93(11):1686-93. PubMed ID: 18835834
[TBL] [Abstract][Full Text] [Related]
31. Treatment with granulocyte colony-stimulating factor after allogeneic bone marrow transplantation for acute leukemia increases the risk of graft-versus-host disease and death: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
Ringdén O; Labopin M; Gorin NC; Le Blanc K; Rocha V; Gluckman E; Reiffers J; Arcese W; Vossen JM; Jouet JP; Cordonnier C; Frassoni F
J Clin Oncol; 2004 Feb; 22(3):416-23. PubMed ID: 14691124
[TBL] [Abstract][Full Text] [Related]
32. A trend towards an increased incidence of chronic graft-versus-host disease following allogeneic peripheral blood progenitor cell transplantation: a case controlled study.
Scott MA; Gandhi MK; Jestice HK; Mahendra P; Bass G; Marcus RE
Bone Marrow Transplant; 1998 Aug; 22(3):273-6. PubMed ID: 9720741
[TBL] [Abstract][Full Text] [Related]
33. Transplantation with higher dose of natural killer cells associated with better outcomes in terms of non-relapse mortality and infectious events after allogeneic peripheral blood stem cell transplantation from HLA-matched sibling donors.
Kim DH; Sohn SK; Lee NY; Baek JH; Kim JG; Won DI; Suh JS; Lee KB; Shin IH
Eur J Haematol; 2005 Oct; 75(4):299-308. PubMed ID: 16146536
[TBL] [Abstract][Full Text] [Related]
34. Role of antithymocyte globulin and granulocyte-colony stimulating factor-mobilized bone marrow in allogeneic transplantation for patients with hematologic malignancies.
Chen XH; Zhang C; Zhang X; Gao L; Gao L; Kong PY; Peng XG; Qi DG; Sun AH; Zeng DF; Liu H; Gong Y; Wang QY
Biol Blood Marrow Transplant; 2009 Feb; 15(2):266-73. PubMed ID: 19167687
[TBL] [Abstract][Full Text] [Related]
35. Reduced-intensity conditioning for allogeneic stem cell transplantation in patients with chronic myeloid leukemia is associated with better overall survival but inferior disease-free survival when compared with myeloablative conditioning - a retrospective study of the Czech National Hematopoietic Stem Cell Transplantation Registry.
Faber E; Koza V; Vitek A; Mayer J; Sedlacek P; Zak P; Zapletalova J; Benesova K; Krejcova H; Steinerova K; Maresova I; Cetkovsky P;
Neoplasma; 2007; 54(5):443-6. PubMed ID: 17688375
[TBL] [Abstract][Full Text] [Related]
36. Reduced intensity conditioning compared with myeloablative conditioning using unrelated donor transplants in patients with acute myeloid leukemia.
Ringdén O; Labopin M; Ehninger G; Niederwieser D; Olsson R; Basara N; Finke J; Schwerdtfeger R; Eder M; Bunjes D; Gorin NC; Mohty M; Rocha V
J Clin Oncol; 2009 Sep; 27(27):4570-7. PubMed ID: 19652066
[TBL] [Abstract][Full Text] [Related]
37. A pilot study of allogeneic bone marrow transplantation using related donors stimulated with G-CSF.
Isola LM; Scigliano E; Skerrett D; Shank B; Ross V; Najfeld V; Fruchtman S
Bone Marrow Transplant; 1997 Dec; 20(12):1033-7. PubMed ID: 9466275
[TBL] [Abstract][Full Text] [Related]
38. Long-term remissions in patients with myelodysplastic syndrome and secondary acute myelogenous leukemia undergoing allogeneic transplantation following a reduced intensity conditioning regimen of 550 cGy total body irradiation and cyclophosphamide.
Hallemeier CL; Girgis MD; Blum WG; Brown RA; Khoury HJ; Devine SM; Vij R; Lin HS; DiPersio JF; Adkins DR
Biol Blood Marrow Transplant; 2006 Jul; 12(7):749-57. PubMed ID: 16785064
[TBL] [Abstract][Full Text] [Related]
39. A comparison of postengraftment infectious morbidity and mortality after allogeneic partially T cell-depleted peripheral blood progenitor cell transplantation versus T cell-depleted bone marrow transplantation.
Broers AE; van der Holt B; Haze S; Braakman E; Gratama JW; Löwenberg B; Cornelissen JJ
Exp Hematol; 2005 Aug; 33(8):912-9. PubMed ID: 16038784
[TBL] [Abstract][Full Text] [Related]
40. Filgrastim-mobilized peripheral blood progenitor cells versus bone marrow transplantation for treating leukemia: 3-year results from the EBMT randomized trial.
Schmitz N; Beksac M; Bacigalupo A; Ruutu T; Nagler A; Gluckman E; Russell N; Apperley J; Szerm J; Bradstock K; Buzyn A; Schlegelberger B; Matcham J; Gratwohl A
Haematologica; 2005 May; 90(5):643-8. PubMed ID: 15921379
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
